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Simple Summary: About 20% of patients with cancer who participate in a phase I clinical trial
discontinue the trial early. Early trial discontinuation is undesirable both for the wellbeing of the
patient as well as for the trial efficiency and the development of new anticancer drugs. We investigated
which clinical predictors at baseline were significantly associated with early trial discontinuation
of patients with cancer who participated in phase I clinical trials. The clinical predictors which
were identified in this study were hyponatremia, elevated alkaline phosphatase level, performance
score of 1 or higher and opioid use. Hyponatremia especially, which was the strongest predictor,
should be considered to be used as an additional eligibility criterion in order to reduce the early trial
discontinuation of patients with cancer who participate in phase I clinical trials.
Abstract: Despite stringent eligibility criteria for trial participation, early discontinuation often
occurs in phase I trials. To better identify patients unlikely to benefit from phase I trials, we in-
vestigated predictors for early trial discontinuation. Data from 415 patients with solid tumors
who participated in 66 trials were pooled for the current analysis. Early trial discontinuation was
defined as (i) trial discontinuation within 28 days after start of treatment or (ii) discontinuation
before administration of the first dosage in eligible patients. Multilevel logistic regression analyses
were conducted to identify predictors for early trial discontinuation. Eighty-two participants (20%)
demonstrated early trial discontinuation. Baseline sodium level below the lower limit of normal
(OR = 2.95, 95%CI = 1.27–6.84), elevated alkaline phosphatase level > 2.5 times the upper limit of
normal (OR = 2.72, 95%CI = 1.49–4.99), performance score ≥ 1 (OR = 2.07, 95%CI = 1.03–4.19) and
opioid use (OR = 1.82, 95%CI = 1.07–3.08) were independent predictors for early trial discontinuation.
Almost 50% of the patients with hyponatremia and all four patients in whom all four predictors
were present together discontinued the trial early. Hyponatremia, elevated alkaline phosphatase
level, performance score ≥ 1 and opioid use were identified as significant predictors for early trial
discontinuation. Hyponatremia was the strongest predictor and deserves consideration for inclusion
in eligibility criteria for future trials.
Keywords: phase I trial; drug development; early trial discontinuation; clinical predictors; hyponatremia
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1. Introduction
Phase I trials in oncology are essential for drug development and evaluation of novel
treatment strategies [1]. Traditionally, phase I trials are designed to test the safety and side
effects of a new drug or treatment strategy, with the aim of establishing the recommended
dose for subsequent trials [2]. Since patients who are referred for phase I trial participation
are usually heavily pretreated, the eligibility criteria for these trials are stringent to minimize
the potential harm of study treatment. To be eligible for participation for most trials,
patients must have an adequate performance status (PS) and organ function and a minimal
life expectancy of 3 months without treatment [1–3]. As a result of these strict criteria,
only 30% of referred patients are eligible, with an insufficient PS being the main reason for
ineligibility [4,5].
Despite the stringent selection, previous studies revealed that 15% of participants in
phase I trials discontinue within three weeks [6]. Patients who discontinue the trial early
are not likely to benefit from study treatment. Moreover, participation in a phase I trial
may yield additional burdens for patients due to possible adverse effects, multiple (long)
visits at the clinic, invasive procedures and sometimes even extra financial costs [7–9]. In
addition, study outcomes are negatively influenced by high rates of patients discontinuing
the trial early. Approximately 70% of early trial discontinuation is due to a deteriorating
condition caused by progressive disease and/or concomitant medical events that are not
related to the study treatment [6]. Furthermore, patients who discontinue trial participation
during the evaluation period because of non-drug-related events need to be replaced for
evaluation of safety and dose limiting toxicity (DLT). The higher accrual necessary for
adequate evaluation is detrimental to the efficient conduct of trials [5,6].
Prevention of early dropout may benefit the conduct and outcome of a trial [2]. In
two previous studies, predictors for early trial discontinuation in participants of phase
I trials conducted before 2010 have been reported [6,10]. The results of these studies
were inconsistent, with the exception of PS and serum alkaline phosphatase, which were
consistently identified as predictors. In addition, these studies are relatively old and
did not include newer treatment strategies such as vaccines, radiopharmaceuticals and
immunotherapy. We here investigated clinical or patient-related predictors of early trial
discontinuation of participants of various types of phase I trials, which could be used as
additional eligibility criteria across trials in the future. Furthermore, we studied the rate
of 90-day mortality, which is a frequently used eligibility criterion in phase I trials [3],
both in patients with and without early trial discontinuation to emphasize that early trial
discontinuation is a relevant measure.
2. Materials and Methods
2.1. Study Design and Population
For the current retrospective analysis, we pooled data from patients with solid tumors
who participated in phase I trials at the Amsterdam UMC, Vrije Universiteit Amsterdam,
in Amsterdam, The Netherlands, and at the Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins in Baltimore, US. The phase I trials were conducted between January
2013 and January 2019. All data were collected in the context of the phase I trial and
were retrieved from the electronic health records of the hospital. All study protocols were
approved by Institutional Review Boards prior to patient recruitment and conducted in
accordance with the International Conference on Harmonization E6 Guidelines for Good
Clinical Practice. All patients provided written informed consent before participation in
the phase I trials.
2.2. Outcome
Early trial discontinuation was defined as (i) trial discontinuation within 28 days of
administration of the first dosage of the investigated drug or (ii) discontinuation before
administration of the first dosage in patients who were found to be eligible after the
screening process. Patients who met these criteria would not have had a chance to benefit
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from the treatment, although they may have experienced toxicity or complications from
treatment or investigations during the screening process. Ninety-day mortality was defined
as (i) death from any cause within 90 days of administration of the first dosage of the
investigated drug or (ii) death from any cause before administration of the first dosage in
patients who were found to be eligible after screening.
2.3. Potential Predictors
Potential predictors and cut-offs were defined before reviewing the data and selected
based on their previously reported association with early trial discontinuation, 90-day mor-
tality, overall survival or clinical relevance in participants of phase I oncology trials [6,10,11].
The following baseline characteristics were selected: opioid use, number of metastatic
sites [6], body mass index (BMI), ECOG/WHO PS [6,10], history of thromboembolism [12],
hemoglobin [13], platelet count [12], white blood cell count [6], lymphocytes [6], absolute
neutrophil count, neutrophils-to-lymphocytes (NTL) ratio [14], serum sodium [15,16], crea-
tinine clearance [10], serum albumin [10], serum alkaline phosphatase [10], serum aspartate
aminotransferase [10], serum alanine aminotransferase [10], serum lactate dehydroge-
nase [6] and the Charlson Comorbidity Index [17]. BMI was calculated from measurements
of body height and weight (body weight/height2, kg/m2). Creatinine clearance was es-
timated by using the Chronic Kidney Disease Epidemiology Collaboration formula [18].
The NTL ratio was calculated by dividing the neutrophils by the lymphocytes. All of the
above predictors were dichotomized according to the cut-off values that were found in the
literature to facilitate interpretability and use in clinical practice (Table 1).
Table 1. Baseline patient characteristics (n = 415).
Characteristic Statistics
Age, mean (SD) years 61 (11)
Sex, n (%) women 204 (49)
Recruited in the Netherlands, n (%) 154 (37)
Primary tumor, n (%)
Gastrointestinal 207 (50)
Genitourinary 42 (10)
Lung cancer 32 (8)
Skin and soft tissue cancer 31 (7)
Breast cancer 28 (7)
Gynecological 19 (5)
Head and neck 18 (4)
Glioblastoma 17 (4)
Neuroendocrine carcinoma 8 (2)
Others 13 (3)




BMI, mean (SD) (kg/m2) 26 (5)
BMI < 18.5, n (%) b 20 (5)
Opioid use, n (%) c 177 (43)
Three or more metastatic sites, n (%) 118 (77)
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Table 1. Cont.
Characteristic Statistics
Any comorbidity other than primary malignancy, n (%) 104 (25)
Diabetes mellitus, n 50
COPD, n 20
Myocardial infarction, n 12
Cerebrovascular accident or transient ischemic attack, n 11
Peripheral vascular disease, n 7
Liver disease, n 7
Peptic ulcer disease, n 7
Kidney disease, n 7
Connective tissue disease, n 6
Heart failure, n 2
History of thromboembolism, n (%) d 57 (14)
Laboratory tests
Hemoglobin (mmol/L) < 7.45, n (%) 221 (53)
White blood cell count (109/L) > ULN, n (%) 62 (15)
Lymphocytes (109/L) < LLN, n (%) e 70 (17)
Neutrophils (109/L) > ULN, n (%) f 56 (14)
Neutrophils-to-lymphocytes (NTL) ratio > 5, n (%) g 154 (38)
Platelets (109/L) > 440, n (%) h 30 (7)
Sodium (mmol/l) < LLN, n (%) i 28 (7)
Creatinine clearance (ml/min/1.73 m2) < 60, n (%) j 56 (14)
Albumin (g/L) < 35, n (%) k 125 (30)
Lactate dehydrogenase (U/L) > 600, n (%) l 34 (11)
AST (U/L) > ULN, n (%) m 132 (32)
ALT (U/L) > ULN, n (%) n 59 (14)
Alkaline phosphatase (U/L) > 2.5 x ULN, n (%) o 67 (16)
a = n − 7, b = n − 2, c = n − 2, d = n − 1, e = n − 3, f = n − 3, g = n − 5, h = n − 1, i = n − 2, j = n − 3,
k = n − 3, l = n − 107, m = n − 8, o = n − 2, p = n − 2, SD = standard deviation, n = number of patients,
ECOG/WHO = Eastern Cooperative Oncology Group/World Health Organization, BMI = body mass index,
COPD = chronic obstructive pulmonary disease, ULN = upper limit of normal, LLN = lower limit of normal,
AST = aspartate aminotransferase, ALT = alanine aminotransferase.
2.4. Statistical Analysis
Univariable and multivariable logistic regression analyses were conducted to identify
factors that were significantly associated with early trial discontinuation. Potentially
relevant variables identified from the univariable analysis were checked for multicolinearity
(r ≥ 0.60). A stepwise forward selection procedure was used to build the multivariable
regression model, starting with the variable that was most strongly associated with the
outcome in the univariable regression model. Subsequently, the next strongest variable
was selected after controlling for the first variable. This procedure was repeated until no
variables with an association with the outcome at a significance level of p < 0.05 could be
added to the model. A random intercept was added to the model to take into account the
clustering of patients within studies. We also checked whether the hospital where the trial
was performed (Amsterdam UMC, Vrije Universiteit Amsterdam versus the Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins), the type of therapy (immunotherapy
versus other types of treatment) or the type of the trial (phase I versus phase I/II) were
non-patient-related predictors of early trial discontinuation, but none of the associations
were statistically significant. As one study (NCT02058901) provided most of the data, we
performed sensitivity analyses on the data excluding that study. Descriptive statistics and
a chi-squared test were used to compare the rate of 90-day mortality both in patients with
and without early trial discontinuation. The odds ratio (OR) and 95% confidence interval
(CI) of the models were reported. Crosstabs were generated to present the proportion of
patients with early trial discontinuation and separately for all the significant predictors
identified in the multivariable analyses. Subsequently, we calculated the positive predictive
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value for the combination of predictors. Analyses were conducted with SPSS version 22
and RStudio version 3.4.2.
3. Results
Data from 415 patients recruited from 66 phase I trials were analyzed. In 21% of the
trials, immunotherapy alone was investigated, in 20% immunotherapy in combination with
targeted therapy, in 18% targeted therapy alone, in 16% targeted therapy in combination
with cytotoxic therapy and in the remaining 25% other types of drugs or combinations
of drugs were investigated (Appendix A). The mean age of the patients was 61 (standard
deviation (SD) = 11) years, half of patients were women and 69% had a PS of 1 (Table 1).
In total, 82 patients (20%) met the criteria for early trial discontinuation. Five patients
(5/82 or 6%) discontinued trial participation before administration of the first dosage. For
the patients who received the first administration of the drug and discontinued the trial
early, the average time to trial discontinuation was 17 days (SD = 7). Thirty-six patients
(44%) discontinued the trial early due to progressive disease, 15 (18%) due to physical
deterioration, 10 patients (12%) due to toxicity that was not dose limiting and 10 patients
(12%) discontinued the trial upon their own request (Table 2).
Table 2. Reasons for early trial discontinuation.
Characteristic n (%)
Early trial discontinuation 82 (20)
Reasons for early trial discontinuation (n = 82) a
Progressive disease 36 (44)
Physical deterioration (not otherwise specified) 15 (18)
Patient’s request 10 (12)
Toxicity (not dose limiting) 10 (12)
Dose-limiting toxicity or serious adverse event 5 (6)
Death 4 (5)
Protocol violation 1 (1)
90-day mortality b 88 (22)
a = n − 1, b = n − 19.
In the multivariable model, a reduced serum sodium level (OR = 2.95, 95%CI = 1.27–6.84),
an elevated alkaline phosphatase level above 2.5 times the upper limit of normal (ULN)
(OR = 2.72, 95%CI = 1.49–4.99), a PS of ≥1 (OR = 2.07, 95%CI = 1.03–4.19) and opioid use
(OR = 1.82, 95%CI = 1.07–3.08) were significantly and independently associated with early
trial discontinuation (Table 3). The positive predictive value for early trial discontinuation
was 46% for hyponatremia, 39% for elevated alkaline phosphatase level, 38% for opioid use
and 31% for PS ≥ 1. Hyponatremia was the predictor with the highest positive predictive
value, based on the fact that 13 (46%) of the 28 patients with hyponatremia discontinued the
trial early. The median (interquartile range) sodium level was 139 (137–141) mmol/L, with
a lower limit of normal of 135 mmol/L in both hospitals. Furthermore, all four predictors
were present in four patients. The positive predictive value in this situation was 100%.
Sensitivity analyses on the data excluding the trial with the most participants yielded
comparable results.
In total, 59% of the patients who discontinued early died within 90 days of starting
the trial compared to 13% of the patients who did not discontinue the trial early (p < 0.001).
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Table 3. Results of the univariable, multivariable and logistic regression analyses for early trial discontinuation.
Predictor
Univariable Analysis Multivariable Analysis
OR (95%CI) p OR (95%CI) p
ECOG/WHO performance status
1 vs. 0 2.98 (1.51–5.86) <0.01 2.07 (1.03–4.19) 0.04
BMI (kg/m2) 0.96 (0.92–1.01) 0.14
<18.5 vs. ≥18.5 2.92 (1.15–7.41) 0.02
Use of opioids vs. non-use 2.44 (1.48–4.01) <0.01 1.82 (1.07–3.08) 0.03
Metastatic sites
≥3 metastatic sites vs. <3 1.45 (0.89–2.35) 0.14
Charlson Comorbidity Score
≥1 vs. 0 0.74 (0.41–1.33) 0.31
History of thromboembolism
Yes vs. no 1.23 (0.63–2.42) 0.54
Laboratory tests
Hemoglobin (mmol/L) < 7.45 1.58 (0.96–2.59) 0.07
White blood cell count (109/L) > ULN 1.67 (0.90–3.11) 0.10
Lymphocytes (109/L) < LLN 1.12 (0.60–2.10) 0.73
Neutrophils (109/L) > ULN 2.20 (1.18–4.11) 0.01
Neutrophils-to-lymphocytes (NTL) ratio > 5 1.52 (0.93–2.49) 0.09
Platelets (109/L) > 440 2.55 (1.16–5.60) 0.02
Sodium (mmol/L) < LLN 4.04 (1.84–8.88) <0.01 2.95 (1.27–6.84) 0.01
Creatinine clearance (mL/min/1.73 m2) < 60 1.00 (0.49–2.03) 1.00
Albumin (g/L) < 35 2.56 (1.55–4.23) <0.01
Lactate dehydrogenase (U/L) > 600 2.25 (1.03–4.93) 0.04
AST (U/L) > ULN 2.22 (1.34–3.68) <0.01
ALT (U/L) > ULN 1.33 (0.69–2.57) 0.39
Alkaline phosphatase (U/L) > 2.5 × ULN 3.36 (1.90–5.93) <0.01 2.72 (1.49–4.99) 0.001
OR = odds ratio, CI = confidence interval, ECOG/WHO = Eastern Cooperative Oncology Group/World Health Organization, BMI = body
mass index, ULN = upper limit of normal, LLN = lower limit of normal, AST = aspartate aminotransferase, ALT = alanine aminotransferase.
Bold: Significant.
4. Discussion
Early trial discontinuation in phase I trials is an important and common problem, for
which a rate of 20% was found in this study. Hyponatremia, PS ≥ 1, opioid use and elevated
alkaline phosphatase level were identified as significant independent predictors for early
trial discontinuation amongst patients who participated in phase I trials. Furthermore, the
rate of 90-day mortality was significantly higher in patients who discontinued the trial
early than in patients who did not.
Importantly, one novel finding is that hyponatremia was identified as a significant
predictor for early trial discontinuation. In earlier studies, hyponatremia has not been
identified or investigated as a potential predictor for early trial discontinuation [6,10] but
was has been to be predictive for 90-day mortality and overall survival in patients partic-
ipating in phase I oncology trials [15,16] and for overall survival in patients with breast,
colorectal and lung cancer [19]. In an ancillary analysis, we found that hyponatremia
was also significantly associated with 90-day mortality (OR = 3.62, 95%CI = 1.63–8.02).
None of the included phase I trials in this study, nor any of the cancer trials examined
in a review [3], used serum sodium level as eligibility criterion. There are several pos-
sible explanations why hyponatremia could be predictive for early trial discontinuation.
Hyponatremia can be caused by the syndrome of inappropriate anti-diuretic hormone
(SIADH) (due to cancer, pain or co-medication), by hypo- or hypervolemia and, although
rare, by reduced salt intake [19]. We could not identify any corresponding clinical etiology
(e.g., comorbidity, use of painkillers, co-medication) for the hyponatremia in the patients
from our trials. Unfortunately, extensive diagnostics (e.g., MRI scan of the brain) to de-
termine the cause of the hyponatremia were not performed in most patients. However,
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hyponatremia may also reflect a more advanced, otherwise undetected, stage of cancer in
general. Further exploration of the etiology and the optimal cut-off value of hyponatremia
should be considered in future studies and, more importantly, the role of hyponatremia as
an eligibility criterion should be further investigated and might be used in future phase
I trials. In the current study, lowering the cut-off value to the threshold of grade 1 hy-
ponatremia (sodium < 130 mmol/L), conforming to the Common Terminology Criteria
for Adverse Events (CTCAE), did not result in a clinically relevant improvement in the
positive predictive value.
The results of the current study also indicated that opioid use was predictive for early
trial discontinuation. The use of opioids has not been investigated earlier as a predictor for
early trial discontinuation or mortality in participants in phase I trials. However, opioid
use is an expression of cancer-related pain, which was found to be a significant predictor
of overall survival in a systematic review and in meta-analysis in patients with different
types of cancer [20,21]. Both PS and an elevated alkaline phosphatase level were identified
as significant predictors of early trial discontinuation. This is in line with two earlier
studies, in which elevated alkaline phosphatase level and PS were identified as significant
predictors for early trial discontinuation in phase I trial participants [6,10].
Almost 60% of the patients with early trial discontinuation died within 90 days.
Both early trial discontinuation and 90-day mortality are most likely caused by early
progression, study-related toxicities, other complications or true inefficacy of the treatment
in combination with an incorrectly estimated life expectancy. Patients who will die within
90 days should not be included in a trial [3] and should be offered advanced care planning,
aggressive symptom management and discussion of end of life [22,23]. A better selection
of patients to be included in a trial might reduce both early trial discontinuation as well as
90-day mortality.
A possible limitation of this study might have been the inclusion of heterogeneous trials
that investigated newer therapies like vaccines, kinase inhibitors and radiopharmaceuticals,
as well as cytotoxic agents. On the other hand, the heterogeneity may enhance the generaliz-
ability of the results to other phase I trials. Furthermore, the current study, with a sample
size of 415 and 82 events, is one of the largest studies evaluating predictors of early trial
discontinuation and made it possible to study up to 8 predictors in the multivariable analysis.
In general, phase I trial participation offers intensified care for cancer-related symp-
toms, which can improve quality of life and may even improve survival [24–26], regardless
of the phase I study drugs administered. This study identified two new predictors for early
trial discontinuation in patients with cancer participating in phase I trials. Notably, a high
positive predictive value of the predictor is important in this setting because participation
could be harmful to patients, but unnecessary exclusion for a potential beneficial drug
is also undesirable. The positive predictive value of hyponatremia is quite high and has
clinical relevance, but sodium level is currently not used as an eligibility criterion. Previous
studies have shown that only 15% of patients experience a clinical benefit from experimen-
tal treatment in phase 1 trials at 6 months [27,28]. This proportion is likely substantially
lower in patients with early trial discontinuation. Due to the low chance of clinical benefit
in combination with the potential harm of participation in a phase I clinical trial, a positive
predictive value of around 50% for early trial discontinuation supports the use of hypona-
tremia as an exclusion criterion and to exclude these patients from participation in phase
I trials.
The results of this study indicate that hyponatremia might be useful for trial selection
and we propose that this criterion deserves further investigation. Changes to the conduct
of early phase trials should be carefully considered because they potentially have far-
reaching effects [29]. Unnecessary restrictive eligibility criteria should be avoided to
maintain generalizability to the patients who will ultimately be treated with the investigated
drugs [30]. More stringent eligibility criteria are warranted if research indicates that patients
have a high risk for an adverse outcome when participating in the study, for example early
trial discontinuation. On the other hand, some eligibility criteria (like brain metastases,
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HIV infection and concurrent malignancies) that are not likely to protect the safety of
trial participants should be loosened or abandoned [30]. As patients with hyponatremia
have a high risk of early trial discontinuation, we hypothesize that adjustment of the
eligibility criteria with the addition of hyponatremia might contribute to a better selection
of patients. Therefore, prospective validation of our results is warranted to determine
whether adjustments of eligibility criteria are needed and to investigate whether the
threshold for hyponatremia could be lowered. In the meanwhile, clinicians should be
alerted that patients with hyponatremia, opioid use, PS ≥ 1 and an elevated alkaline
phosphatase level are at risk for an unfavorable outcome and should be closely monitored,
with appropriate initiation of supportive or palliative care if needed.
5. Conclusions
In conclusion, hyponatremia, opioid use, PS ≥ 1 and an elevated alkaline phosphatase
level were identified as predictors for early trial discontinuation amongst patients with
cancer participating in phase I trials. Hyponatremia was the strongest predictor with a
positive predictive value of 46% and discussion should be centered on this as a possible
exclusion criterion in future phase I trials in oncology. Furthermore, the rate of 90-day
mortality was significantly higher in patients who discontinued the trial early than in
patients who did not.
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Appendix A
Table A1. Characteristics of included trials.
EUdraCT/NCT Trial
Number: Title Population Participants, n
NCT02058901 High-dose protein kinase inhibitor Solid tumors 81
NCT02636426 High-dose protein kinase inhibitor Solid tumors 18
2011–005116-28 Cytotoxic drug in combination withradiopharmaceutical Prostate cancer 6





2015–000673-12 DNA-dependent protein kinase inhibitor Solid tumors 4






2013–003041-41 Targeted immunocytokine (CEA-IL2v) Solid tumors 11
2013–002663-25 Vaccine (hVEGF26–104/RFASE) Solid tumors 25
NCT00989651
A Phase I Study of Intravenous Carboplatin/Paclitaxel
or Intravenous and Intraperitoneal
Paclitaxel/Cisplatin in Combination with Continuous
or Intermittent ABT-888 and Bevacizumab in Newly
Diagnosed Patients with Previously Untreated
Epithelial Ovarian, Fallopian Tube or Primary
Peritoneal Cancer.
Epithelial ovarian,




An Early Phase 1 Study of ABT-888 in Combination
with Carboplatin and Paclitaxel in Patients with
Hepatic or Renal Dysfunction and Solid Tumors.
Solid tumors 1
NCT01351103
A Phase I, open-label, dose escalation study of oral
LGK974 in patients with malignancies dependent on
Wnt ligands
Advanced solid tumors 2
NCT01587703
A Phase I/II Open-Label, Dose Escalation Study to
Investigate the Safety, Pharmacokinetics,
Pharmacodynamics, and Clinical Activity of
GSK525762 in Subjects with NUT Midline Carcinoma
(NMC) and Other Cancers
NUT midline carcinoma
(NMC) and other cancers 1
NCT01693562
A Phase 1/2 Study to Evaluate the Safety, Tolerability,
and Pharmacokinetics of MEDI4736 in Subjects With
Advanced Solid Tumors.
Advanced solid tumors 1
NCT01783171
A Phase I Trial of Dinaciclib (SCH727965) and MK2206
in Metastatic Pancreatic Cancer with an Expansion




A Phase 1/2a Dose Escalation and Cohort Expansion
Study of the Safety, Tolerability, and Efficacy of
Anti-LAG-3 Monoclonal Antibody (BMS-986016)
Administered Alone and in Combination with
Anti-PD-1 Monoclonal Antibody (Nivolumab,
BMS-936558) in Advanced Solid Tumors
Advanced solid tumors 27
NCT02048384
An Exploratory Study of Metformin With or Without
Rapamycin as Maintenance Therapy After Induction
Chemotherapy in Subjects with Metastatic Pancreatic
Adenocarcinoma
Pancreatic cancer 7
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Table A1. Cont.
EUdraCT/NCT Trial
Number: Title Population Participants, n
NCT01749397
A Phase I Trial of the Combination of the PARP
Inhibitor ABT-888 with Intraperitoneal Floxuridine







A Phase 1, Multicenter, Open-Label, Dose-Escalation
and Expansion, Safety, Pharmacokinetic,
Pharmacodynamic, and Clinical Activity Study of
Orally Administered AG-120 in Subjects with
Advanced Solid Tumors, Including Glioma, with an
IDH1 Mutation.
Advanced solid tumors 3
NCT02248805
A Phase 1, First-in-Human, Open Label, Dose
Escalation Study of MGD007, A Humanized gpA33 x
CD3 Dual-Affinity Re-Targeting (DART®) Protein in





A Phase 1b Open-label Study to Evaluate the Safety
and Tolerability of MEDI4736 in Combination with





A Phase 1 Study of HyperAcute Renal (HAR)
Immunotherapy In Patients with Metastatic Renal Cell
Cancer
Advanced renal cell cancer 1
NCT02501902
An open-label phase IB study of Palbociclib (oral CDK
4/6 inhibitor) plus Abraxane (Nab-paclitaxel) in





An Open-Label, Phase 1 Study of the Safety and
Immunogenicity of JNJ-64041809, a Live Attenuated
Listeria monocytogenes Immunotherapy, in Subjects
with Metastatic Castration-resistant Prostate Cancer
Prostate cancer 5
NCT02592967
An Open-Label, Phase 1 Study of the Safety and
Immunogenicity of JNJ-64041757, a Live Attenuated
Listeria monocytogenes Immunotherapy, in Subjects
With Non-Small Cell Lung Cancer
Non-small-cell lung cancer 5
NCT02319018
A Phase 1 Study of alisertib (MLN8237) in




Phase I/Ib, single-arm, open-label, multi-center trial
using ARQ-761 (beta-lapachone) treatment with
gemcitabine/nab-paclitaxel chemotherapy in




A Phase 1 study to evaluate the safety, tolerability, and
immunogenicity of EGFR (Vectibix®
sequence)-targeted EDVs containing doxorubicin
(EGFR(V)-EDV-Dox) in subjects with recurrent
glioblastoma multiforme (GBM)
Recurrent glioblastoma 6
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Table A1. Cont.
EUdraCT/NCT Trial
Number: Title Population Participants, n
NCT02716948
A Pilot Study of Stereotactic Radiosurgery combined
with Nivolumab in Patients with Newly Diagnosed
Melanoma Metastases in the Brain and Spine
Melanoma 4
NCT02588443
Phase I study of neo-adjuvant RO7009789 alone or
neo-adjuvant RO7009789 plus nab-paclitaxel and
gemcitabine followed by adjuvant RO7009789 plus
nab-paclitaxel and gemcitabine for patients with
newly diagnosed resectable pancreatic carcinoma.
Pancreatic cancer 3
NCT02453620
A Phase 1 Study Evaluating Safety, Tolerability, and
Preliminary Antitumor Activity of Entinostat and
Nivolumab with or without Ipilimumab in Advanced
Solid Tumors
Advanced solid tumors 12
NCT02572687
An Open-Label, Multicenter, Phase 1 Study of
Ramucriumab Plus MEDI4736 in Patients with Locally
Advanced and Unresectable or Metastatic
Gastrointestinal or Thoracic Malignancies
Advanced gastrointestinal
or thoracic malignancies 1
NCT01804530
A Phase 1 Study to Assess Safety, Pharmacokinetics,
and Pharmacodynamics of PLX7486-TsOH as a Single
Agent and in Combination with Gemcitabine and
nab-Paclitaxel in Patients with Advanced Solid
Tumors.
Advanced solid tumors 4
NCT02512172
A study of using epigenetic modulators to enhance




A Pilot Study of Dexamethasone Therapy Prior to
Rechallenge with Enzalutamide in Men with
Metastatic Castration-Resistant Prostate Cancer Dex
EXTends Enza Response (The DEXTER Trial)
Prostate cancer 1
NCT02358473
Open-label, Multicenter Phase 1 Study of
Mogamulizumab (KW-0761) in Combination with
Docetaxel in Previously Treated Subjects with
Non-small Cell Lung Cancer (NSCLC)
Non-small-cell lung cancer 1
NCT02355535 Phase I Study of Procaspase Activating Compound-1(PAC-1) in the Treatment of Advanced Malignancies Advanced solid tumors 7
NCT02262741
A Phase 1 Study to Evaluate the Safety, Tolerability,
and Efficacy of MEDI4736 in Combination with
Tremelimumab in Subjects with Recurrent or
Metastatic Squamous Cell Carcinoma of the Head and
Neck.
Advanced head and neck
cancer 1
NCT02619253
A Phase I/Ib, Open Label, Dose Finding Study to
Evaluate Safety, Pharmacodynamics and Efficacy of
Pembrolizumab (MK-3475) in Combination with
Vorinostat in Patients with Advanced Renal or
Urothelial Cell Carcinoma
Advanced renal or
urothelial cell carcinoma 11
NCT02890069
Phase Ib, open-label, multi-center study to
characterize the safety, tolerability and
pharmacodynamics (PD) of PDR001 in combination
with LCL161, everolimus (RAD001) or panobinostat
Advanced solid tumors 10
NCT02631733 A Phase I Study of a Combination of MM-398 andVeliparib in Solid Tumors Advanced solid tumors 2
NCT02833883
A Phase 1b Study of Enzalutamide plus CC-115 in
Men with Castration-Resistant Prostate Cancer
(CRPC)
Prostate cancer 5
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Table A1. Cont.
EUdraCT/NCT Trial
Number: Title Population Participants, n
NCT02989636
Phase I Safety Study of Stereotactic Radiosurgery with
Concurrent and Adjuvant PD-1 Antibody Nivolumab
in Subjects with Recurrent or Metastatic Chordoma
Advanced chordoma 3
NCT03043989
Two independent phase 1b cohorts of docetaxel or




A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose,
Dose-Selection Study of CPI-444 as Single Agent and
in Combination with Atezolizumab in Patients with
Selected Incurable Cancers
Advanced solid tumors 14
NCT02819999
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in
the Frontline Treatment of Patients with Extensive
Stage Small Cell Lung Cancer
Small-cell lung cancer 1
NCT02520778
9903 A Phase 1B Study of AZD9291 in Combination
with Navitoclax in EGFR-Mutant Non-Small Cell
Lung Cancer Following Resistance to Initial EGFR
Kinase Inhibitor
Non-small-cell lung cancer 1
NCT03051477 A Phase I Dose Escalating Trial of Mistletoe Extract inPatients with Advanced Solid Tumors Advanced solid tumors 12
NCT02608125
A Phase 1 Open-Label, Multicenter, Dose-Escalation
Study of PRN1371, a FGFR1–4 Kinase Inhibitor, in
Adult Patients with Advanced Solid Tumors, followed
by an Expansion Cohort in Patients with FGFR1, 2, 3,
or 4 Genetic Alterations
Advanced solid tumors 2
NCT02722538
A Phase 1b, Multicenter, Open Label Study Evaluating
Safety, Tolerability and Preliminary Efficacy of
GemRIS 225 mg in Subjects with Muscle-Invasive
Transitional Cell Carcinoma of the Bladder
Bladder cancer 1
NCT02903914
Safety, Pharmacokinetics, and Pharmacodynamics of
Escalating Oral Doses of the Arginase Inhibitor
INCB001158 (formerly known as CB-1158) as a Single
Agent and in Combination with Immune Checkpoint
Therapy in Patients with Advanced/Metastatic Solid
Tumors
Advanced solid tumors 8
NCT03246074 Phase I Clinical Trial of Combined Fostamatinib andPaclitaxel in Ovarian Cancer Ovarian cancer 3
NCT03148418
An Open-Label, Multicenter Extension and Long-term
Observational Study in Patients Previously Enrolled in
a Genentech and/or F. Hoffman-La Roche LTD
Sponsored Atezolizumab Study
Advanced solid tumors 1
NCT3238027
A Phase 1, Open-Label, Dose Escalation Trial to
Investigate the Safety, Tolerability, Pharmacokinetics
and Pharmacodynamic Activity of SNDX-6352
Monotherapy and SNDX-6352 in Combination with
Durvalumab in Patients with Unresectable, Recurrent,
Locally-Advanced, or Metastatic Solid Tumors
Advanced solid tumors 10
NCT03219268
A Phase 1, First-in-Human, Open-Label, Dose
Escalation Study of MGD013, A Bispecific DART®
Protein binding PD-1 and LAG-3 in Patients with
Unresectable or Metastatic Neoplasms
Advanced solid tumors 6
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Table A1. Cont.
EUdraCT/NCT Trial
Number: Title Population Participants, n
NCT03058289
A Phase 1/2 Safety Study of Intratumorally
Administered INT230–6 in Adult Subjects with
Advanced Refractory Cancers
Advanced solid tumors 2
NCT03299946
Feasibility and Efficacy of Neoadjuvant Cabozantinib
plus Nivolumab (CaboNivo) Followed by Definitive





A Phase 1 Open-label Dose Escalation and Dose
Expansion Study of CGX1321 in Subjects with
Advanced Solid Tumors and Phase 1b Study of
CGX1321 in Combination with Pembrolizumab in




A Phase Ib Study of Guadecitabine (SGI-110) and












Phase Ib, open-label, multi-center study to
characterize the safety, tolerability and
pharmacodynamics (PD) of PDR001 in combination
with CJM112, EGF816, Ilaris® (canakinumab) or
Mekinist® (trametinib)
Advanced solid tumors 1
2437136
A Phase 1b/2, Open-label, Dose Escalation Study of
Entinostat in Combination with Pembrolizumab in
Patients with Non-small Cell Lung Cancer, with
Expansion Cohorts in Patients with Non-small Cell








An Open-label, Phase I, Dose Escalation Trial of
Methionine Aminopeptidase 2 Inhibitor M8891 in
Subjects with Advanced Solid Tumors
Advanced solid tumors 3
3137888
Pilot study of spectroscopic MRI-guided,




Phase I Study of AZD1775 (adavosertib) with
Radiation and Temozolomide in Patients with Newly
Diagnosed Glioblastoma and Evaluation of




Phase 1 Dose Escalation and Drug Distribution Study




A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone
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